This study investigates a novel targeted therapy which combines the α-emitter Bismuth-213 (213Bi) and HER2-targeting nanobodies (Nbs) to selectively kill HER2+ metastases in breast- and ovarian cancer. The use of nanobodies as vehicles in TAT is promising due to their excellent in vivo properties, high affinity and specificity, fast diffusion and clearance kinetics. Moreover, Nbs show good tumor penetration due to their small size. The aim of this study is to develop and evaluate the in vitro binding characteristics on HER+ SKOV-3 cells, the in vitro stability using radio-ITLC and HPLC and the in vivo biodistribution of 213Bi-DTPA HER2 targeting Nb.
DEKEMPENEER Yana;
CAVELIERS Vicky;
D'HUYVETTER Matthias;
MAERTENS Dominic;
GYSEMANS M.;
OOMS Maarten;
LAHOUTTE Tony;
XAVIER Catharina;
BRUCHERTSEIFER Frank;
MORGENSTERN Alfred;
CARDINAELS Thomas;
2019-07-24
ELSEVIER BV
JRC116460
1939-8654 (online),
https://publications.jrc.ec.europa.eu/repository/handle/JRC116460,
10.1016/j.jmir.2019.03.024 (online),
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Additional supporting files
| File name | Description | File type | |
|---|
